SEC Form 4	
------------	--

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b)
\cup	Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden

L		
	hours per response:	0.5
	Estimated average burden	

1. Name and Address of Reporting Ferson			2. Issuer Name and Ticker or Trading Symbol Kura Oncology, Inc. [KURA]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)					
<u>Martell Bridg</u>	<u>get A</u>		<u>rear oncorosy, me.</u> [rotar]		Director	10% Owner			
				X	Officer (give title below)	Other (specify below)			
(Last) C/O KURA ON	(First) COLOGY, INC.	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) 02/10/2020		Acting Chief Medica	,			
3033 SCIENCE	PARK RD, SUITI	E 220							
(Street)			4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Indivi Line)	idual or Joint/Group Filing (Check Applicable			
SAN DIEGO	СА	92121		X	Form filed by One Report	ing Person			
					Form filed by More than C Person	One Reporting			
(City)	(State)	(Zip)							

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transa Code (8)	ction	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	v	Amount (A) or (D) Price		Price	Transaction(s) (Instr. 3 and 4)		(1130. 4)

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

				-											
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Option to purchase common stock	\$12.22	02/10/2020		A		50,000		(1)	02/09/2030	Common Stock	50,000	\$0.00	50,000	D	
Option to purchase common stock	\$12.22	02/10/2020		A		50,000		(2)	02/09/2030	Common Stock	50,000	\$0.00	50,000	D	

Explanation of Responses:

1. This option vests in full on the one year anniversary of the date of grant.

2. 1/4th of the shares vest on the one year anniversary of the date of grant, and 1/48th of the shares vest in 36 monthly installments thereafter.

Remarks:

James Basta, Attorney-in-fact for Bridget Martell

02/12/2020

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.